TY - JOUR
T1 - Trends in statin use and low-density lipoprotein cholesterol levels among US adults
T2 - Impact of the 2001 National Cholesterol Education Program guidelines
AU - Mann, Devin
AU - Reynolds, Kristi
AU - Smith, Donald
AU - Muntner, Paul
PY - 2008/9
Y1 - 2008/9
N2 - BACKGROUND: Few data are available on the use of statins after publication of the National Cholesterol Education Program Third Adult Treatment Panel (ATP-III) guidelines in 2001. OBJECTIVE: To determine changes in statin use and its impact on low-density lipoprotein cholesterol (LDL-C) control among US adults from 1999 to 2004. METHODS: High LDL-C levels and statin use among 1911 participants of the National Health and Nutrition Examination Survey (NHANES) 2003-2004 were determined and compared with 1770 and 2094 participants of NHANES 1999-2000 and NHANES 2001-2002, respectively. Statin use was obtained from review of participants' drug containers. High LDL-C levels and LDL-C control were defined, using risk-specific cut-points from the ATP-III guidelines. RESULTS: Statins were taken by 24 million Americans in 2003-2004. an increase from 12.5 million in 1999-2000. In 1999-2000, 2001-2002. and 2003-2004, statins were being used by 19.6%, 27.3%, and 35.9% of US adults with high LDL-C levels, respectively (p trend <0.001). Age-standardized mean LDL-C declined from 119.9 to 112.0 to 100.7 mg/dL among statin users between 1999-2000, 2001-2002, and 2003-2004. LDL-C control to ATP-III recommended targets was achieved by 49.7%, 67.4%, and 77.6% of statin users in 1999-2000, 2001-2002, and 2003-2004, respectively (p trend <0.001). Among US adults with high LDL-C, after multivariate adjustment, non-Hispanic blacks were 39% less likely (prevalence ratio = 0.61; 95 CI 0.39 to 0.97) than non-Hispanic whites to be taking statins. CONCLUSIONS: Statin use continues to increase among US adults and this has led to substantial improvements in LDL-C control. Nevertheless, suboptimal statin use. especially among racial/ethnic minorities, continues to prevent the maximal public health benefit from this effective drug class.
AB - BACKGROUND: Few data are available on the use of statins after publication of the National Cholesterol Education Program Third Adult Treatment Panel (ATP-III) guidelines in 2001. OBJECTIVE: To determine changes in statin use and its impact on low-density lipoprotein cholesterol (LDL-C) control among US adults from 1999 to 2004. METHODS: High LDL-C levels and statin use among 1911 participants of the National Health and Nutrition Examination Survey (NHANES) 2003-2004 were determined and compared with 1770 and 2094 participants of NHANES 1999-2000 and NHANES 2001-2002, respectively. Statin use was obtained from review of participants' drug containers. High LDL-C levels and LDL-C control were defined, using risk-specific cut-points from the ATP-III guidelines. RESULTS: Statins were taken by 24 million Americans in 2003-2004. an increase from 12.5 million in 1999-2000. In 1999-2000, 2001-2002. and 2003-2004, statins were being used by 19.6%, 27.3%, and 35.9% of US adults with high LDL-C levels, respectively (p trend <0.001). Age-standardized mean LDL-C declined from 119.9 to 112.0 to 100.7 mg/dL among statin users between 1999-2000, 2001-2002, and 2003-2004. LDL-C control to ATP-III recommended targets was achieved by 49.7%, 67.4%, and 77.6% of statin users in 1999-2000, 2001-2002, and 2003-2004, respectively (p trend <0.001). Among US adults with high LDL-C, after multivariate adjustment, non-Hispanic blacks were 39% less likely (prevalence ratio = 0.61; 95 CI 0.39 to 0.97) than non-Hispanic whites to be taking statins. CONCLUSIONS: Statin use continues to increase among US adults and this has led to substantial improvements in LDL-C control. Nevertheless, suboptimal statin use. especially among racial/ethnic minorities, continues to prevent the maximal public health benefit from this effective drug class.
KW - Low-density lipoprotein cholesterol
KW - National Cholesterol Education Program Third Adult Treatment Panel
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=50249123047&partnerID=8YFLogxK
U2 - 10.1345/aph.1L181
DO - 10.1345/aph.1L181
M3 - Article
C2 - 18648016
AN - SCOPUS:50249123047
SN - 1060-0280
VL - 42
SP - 1208
EP - 1215
JO - Annals of Pharmacotherapy
JF - Annals of Pharmacotherapy
IS - 9
ER -